Dissemination (Meeting Coverage)

In a randomized-controlled trial, cognitive rehabilitation therapy (CRT) and mindfulness-based...

Discontinuing natalizumab during the first trimester of pregnancy increased relapse risk during...

Do disease-modifying therapies (DMTs) in everyday practice delay the progression of disease in...

New research suggests that not only is MS preceded by Epstein-Barr virus (EBV) infection, but it...

Immune ablation with autologous hematopoietic stem cell transplantation (AHSCT) was not superior...

Disease progression independent of relapse activity (PIRA) was found to be less frequent in...

Treatment with ravulizumab was highly effective in reducing risk for relapse in patients with...

A large amount of preclinical and clinical research has been dedicated to remyelination in MS,...

A non-inferiority comparative study failed to demonstrate that treatment with rituximab is...

An analysis of patient-reported outcomes (PRO) over a 10-year period suggests that physical...

Non-disabling relapses (NDRs) that occur early in the course of relapsing-remitting MS (RRMS) are...

For the first time, a randomized, placebo-controlled trial demonstrated beneficial effects of a...

For a presentation at the 2022 European Committee for Treatment and Research in Multiple Sclerosis...

Data from a randomized controlled trial presented at the European Committee for Treatment and...

A prospective, longitudinal, multicenter study of 217 patients with neuromyelitis optica spectrum...

A new study suggests B-cell depleting anti-CD20 monoclonal antibodies (mAbs) such as ocrelizumab...

Anti-CD20 therapies do not fully resolve chronic, active/smoldering lesions, visible on MRI as...

For a variety of reasons, patients with relapsing-remitting MS (RRMS) together with their...